>

Stephen Doster

  • Vanderbilt University

    The Skaar lab discovers how bacterial pathogen survives without water

    The pathogen Acinetobacter baumannii can survive on hospital surfaces — without water — for months, an ability that has helped it become a leading cause of hospital-acquired infections. Now, a team of Vanderbilt researchers has discovered a mechanism this bug uses to live in a dried-out state: it produces “hydrophilin”… Read More

    May. 5, 2022

  • New faculty Nancy Carrasco - Molecular Physiology, in her lab at Light Hall for Vanderbilt Magazine.

    Carrasco elected to American Academy of Arts and Sciences

    The American Academy of Arts and Sciences announced today that Dr. Nancy Carrasco, Joe C. Davis Professor of Biomedical Science and professor and chair of molecular physiology and biophysics, has been elected as one of its new members. Carrasco was elected to… Read More

    Apr. 29, 2022

  • Vanderbilt University

    Ramadan from the inside

    By Ansari Aleem Ansari Aleem, Ph.D. For me, Ramadan—the month of fasting—is about the Quran, worship, prayer, and generosity. Fasting is one of the pillars of Islam and is mandatory for a healthy adult Muslim. I have been practicing fasting ever since I can remember. For me, fasting is a… Read More

    Apr. 26, 2022

  • Vanderbilt University

    Collaborative research lays groundwork for potential treatment of a rare and deadly type of cancer

    A collaborative project between the labs of William Tansey, Ingram Professor of Cancer Research and professor of cell and developmental biology and biochemistry, and Stephen Fesik, Orrin H. Ingram II Chair in Cancer Research and professor of biochemistry, chemistry and pharmacology, has… Read More

    Apr. 25, 2022

  • Vanderbilt University

    Prothena and Warren Center for Neuroscience Drug Discovery collaborate on new Alzheimer’s disease therapeutics

    Prothena and the Warren Center for Neuroscience Drug Discovery have entered into a collaborative research agreement to develop new small molecule therapeutics for the treatment of Alzheimer’s disease in individuals with Down syndrome. Down syndrome is a condition in which a person’s having… Read More

    Apr. 22, 2022

  • Vanderbilt University

    Attend ‘Survivor: Intersections of Cancer and Mental Health with Ethan Zohn’ on April 26

    Ethan Zohn, winner of the CBS reality show Survivor, two-time cancer survivor, humanitarian and former professional soccer player, will discuss his journey with reality television, cancer, mental health and humanitarian work as part of the School of Medicine Basic Sciences’ monthly Lab-to-Table Conversations on Tuesday, April… Read More

    Apr. 8, 2022

  • Vanderbilt University

    Study advances understanding of bacterial bioterrorism agent

    Vanderbilt researchers have identified a critical regulatory factor in Bacillus anthracis, the bacterium that causes the disease anthrax and has been used as a biological weapon. The findings, reported in the journal Nature Communications, provide new insights into bacterial gene regulation and may guide novel antibacterial therapeutic… Read More

    Apr. 8, 2022

  • Vanderbilt University

    New prognosis predictor and target for gastric cancer

    Treatment resistance is especially pronounced in gastric cancer and contributes to patient mortality, highlighting the need for resensitization strategies. Robert Coffey, MD, Xiaodi Zhao, PhD, and colleagues compared the secretome, or secreted proteins, of chemoresistant and chemosensitive human gastric cancer cell lines to identify biomarkers of resistance. Read More

    Apr. 8, 2022

  • Vanderbilt University

    Vanderbilt University, Medical Center reach $1B milestone together in research funding

    Scholars at Vanderbilt University and Vanderbilt University Medical Center achieved a significant milestone in 2021: more than $1 billion in research funding awarded from external organizations. Vanderbilt’s global leadership in research—from biomedical and biotechnology discoveries to vaccine development to groundbreaking advances in computer science, education and psychology—contributed to this landmark… Read More

    Apr. 5, 2022

  • Vanderbilt University

    WCNDD-developed Parkinson’s drug to enter next phase of clinical trial

    A drug aimed at improving the lives of patients living with Parkinson’s disease will go to the next phase of clinical trials, thanks to a $13.5 million investment raised by Nashville’s Appello Pharmaceuticals. The clinical-stage pharmaceutical company that focuses on nervous system disorders announced Tuesday that its lead drug,… Read More

    Apr. 4, 2022